UPC Analytics
ENDE
Overview · Filed: —

ACT_597355/2023

METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)

InfringementMain Infringement ActionDusseldorf LDInfringement Action—
OverviewDecisionsReasoningCitationsDocumentsTimeline
Parties

Claimants

  • Sanofi Biotechnologies SAS
  • Regeneron Pharmaceuticals Inc.
Reps: Niels Hölder (HOFFMANN EITLE PartmbB); Mike Gruber (HOFFMANN EITLE PartmbB); Michael Pfeifer (HOFFMANN EITLE PartmbB); Daniel Wise (Carpmaels & Ransford LLP); Agathe Michel-De Cazotte (Carpmaels & Ransford LLP)

Respondents

Reps: null
Judges
  • Ronny ThomasPresiding judge
  • Anna Bérénice ThomLegally qualified judge
  • András Ferenc KupeczLegally qualified judge
  • Xavier Thomas Olivier Dorland-GalliotTechnically qualified judge
Patents
  • EP3536712
CPC codes: A61K39/3955, C07K2317/76, A61P9/00, A61P43/00, A61P27/02, C07K2317/21, A61P7/00, C07K16/40, A61K2039/505, A61P11/00, A61P3/06, A61P9/10

Technology area: Pharmaceuticals · Antibody/Biologics

Sector: Organic Chemistry

Outcome
Not infringedNot infringed
Filed: —
First decided: May 13, 2025
Language: —

The Düsseldorf Local Division dismissed Sanofi and Regeneron's infringement action and Amgen's counterclaim for revocation concerning EP3536712 (a second medical use patent for evolocumab in paediatric patients), finding no infringement of the second medical use claim and that the counterclaim for revocation was also unfounded, with each side bearing the costs of the proceedings they lost.

Claims
At issueall
Not infringedall
Notes: Düsseldorf LD dismissed infringement action on second medical use claim of EP3536712 B1 and dismissed counterclaim for revocation; no specific claim numbers enumerated in operative order.